类风湿关节炎与年龄对绝经后女性掌骨干几何与密度的影响:纵向pQCT研究
即使接受生物制剂治疗,低剂量糖皮质激素仍影响掌骨干几何与密度。
要点
- RA状态与掌骨皮质骨密度丢失独立相关(交互效应-3.08 mg/mm3,P=0.014)。
- 泼尼松≥5 mg/天与髓腔CSA增加四倍及皮质密度和CSA丢失相关。
- 基线高疾病活动且高GC剂量者总CSA增加但皮质BMD仍下降。
核心结论
- 掌骨髓腔CSA增加和皮质变薄是生理性时间依赖过程,RA状态与皮质骨密度丢失相关。
- 即使接受生物制剂治疗,低剂量糖皮质激素仍随时间影响掌骨干几何与密度。
研究设计与样本
- 在基线及随访时对第三掌骨干50%处行外周定量CT扫描,随访63个月。
- 监测双膦酸盐、糖皮质激素、生物制剂和改善病情抗风湿药使用,采用线性混合效应模型分析。
主要发现
- RA和健康对照均呈现髓腔CSA时间依赖性增加(+0.41 mm2/年,P<0.0001),总CSA保持稳定(P=0.2)。
- RA状态与皮质骨密度丢失相关(交互效应:-3.08 mg/mm3;P=0.014)。
- RA亚组中GC≥5 mg/天与髓腔CSA增加四倍正相关(0.67 mm2/年,P=0.009),并导致皮质密度丢失三至四倍(-6.6 mg/mm3/年;P=0.002)和皮质CSA丢失(-0.57 mm2/年,P=0.004)。
- 基线高疾病活动且高GC剂量患者总CSA增加(0.29 mm2/年;P=0.049)且皮质BMD丢失(-5.73 mg/mm3/年;P=0.05),尽管临床反应良好。
临床怎么用
- 对绝经后RA患者应关注掌骨皮质骨密度丢失,尤其使用糖皮质激素者。
- 即使低剂量GC(≥5 mg/天)也可能影响骨几何与密度,需权衡GC使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to elucidate the effects of changes in the geometry and density of the metacarpal bone of patients with rheumatoid arthritis (RA). METHODS: This prospective study included consecutive postmenopausal RA patients who met the American College of Rheumatology Criteria and healthy controls (HC). Peripheral quantitative computed tomography scans at 50% of the total metacarpal shaft (third metacarpal bone) were obtained at baseline and follow-ups. Use of bisphosphonates (BP), glucocorticoids (GC), biologics, and disease-modifying anti-rheumatic drugs (DMARD) was monitored (baseline to follow-up). Total cross-sectional area (CSA), cortical-transitional zone and compact zone CSA, cortical volumetric bone mineral density, and compact cortex porosity were measured. A linear mixed-effects model was used to determine significant differences in the rate of change in the RA and control groups and in RA patient subgroups. RESULTS: Thirty-nine RA patients and 42 consecutive postmenopausal HC were followed for 63 months. RA and HC depicted a time-dependent increase of medullary CSA (+0.41 mm2/year, P < 0.0001), while total CSA remained stable (P = 0.2). RA status was associated with a loss of cortical bone mineral density (interaction: -3.08 mg/mm3; P = 0.014). In RA subgroup analysis, GC use ≥5 mg/day was positively correlated with a fourfold increase of medullary CSA (0.67 mm2/year P = 0.009), which resulted in a three- to fourfold loss of cortical density (-6.6 mg/mm3/year; P = 0.002) and cortical CSA (-0.57 mm2/year, P = 0.004). Patients with high disease activity and high GC dose at baseline demonstrated an increase in the total CSA (0.29 mm2/y; P = 0.049) and a loss of cortical BMD (-5.73 mg/mm3/y; P = 0.05) despite good clinical response. CONCLUSION: Increase in medullary metacarpal CSA and thinning of the cortical CSA are physiological and time dependent. RA status is associated with loss in cortical density. Even upon biological therapy, low glucocorticoid dose affects metacarpal bone shaft geometry and density over time.
引用
- Aeberli D, Fankhauser N, Zebaze R, et al. Effect of rheumatoid arthritis and age on metacarpal bone shaft geometry and density: A longitudinal pQCT study in postmenopausal women. Semin Arthritis Rheum. 2019. PMID: 31466837. doi:10.1016/j.semarthrit.2019.08.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。